MarginsXMarginsX
Home › Markets › Health Care › MEDP

Medpace Holdings Inc. (MEDP)

MEDP trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$648.20
-0.88% on the day
Market cap
$18.1B
Large cap
Revenue · 2025
$2.5B
+20.0% on 2024
Net income · 2025
$451.1M
17.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1668397/000166839726000006/0001668397-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMEDP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Commercial Physical & Biological Resarch
CountryUnited States
IPO year2016
SEC CIK0001668397
SEC industry codeServices-Commercial Physical & Biological Research
Incorporated inDE

Financials · 2025

LineValue
Revenue$2.5B
Net income$451.1M
Operating income$534.9M
Net margin17.8%
Operating margin21.1%
Revenue growth+20.0%
Cash$497.0M
Total assets$2.0B
P/E (computed)40.2×
P/S (computed)7.2×

Warning signs

Cash runway
Cash-flow positive
$705.3M cash at September 30, 2026
Share count, 1 year
-0.7%
2025-10-17 to 2026-10-16 · -8.8% over 3 years
Going-concern doubt
No
10-Q filed October 22, 2026
Insider net buying, 12 months
-$436.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-22
Cash and burn$705.3M cash; operating cash flow $180.8M a quarter.Report 2026-09-30
Shares outstanding27,971,686 (2026-10-16); 28,168,223 a year earlier; 30,683,436 three years earlier.Cover page 2026-10-16
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Cincinnati, Ohio, United StatesPCAOB Form AP 2026-02-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $436.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$716.0M$137.5M$216.6M$705.3MNo debt tags$2.8B10-Q 2026-10-22
Q2 2026
2026-06-30
$707.3M$121.4M$162.0M$502.7MNo debt tags$2.8B10-Q 2026-07-23
Q1 2026
2026-03-31
$706.6M$123.9M$151.8M$652.7MNo debt tags$2.7B10-Q 2026-04-23
Q4 2025
2025-12-31
$708.5M$135.1M$192.7M$497.0MNo debt tags$2.5B10-K 2026-02-10
Q3 2025
2025-09-30
$659.9M$111.1M$246.2M$285.4MNo debt tags$2.4B10-Q 2026-10-22
Q2 2025
2025-06-30
$603.3M$90.3M$148.5M$46.3MNo debt tags$2.2B10-Q 2026-07-23
Q1 2025
2025-03-31
$558.6M$114.6M$125.8M$441.4MNo debt tags$2.2B10-Q 2026-04-23
Q4 2024
2024-12-31
$536.6M$117.0M$190.7M$669.4MNo debt tags$2.1B10-K 2026-02-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2023-02-14
Latest annual report10-K2026-02-10
Latest quarterly / interim10-Q2026-10-22
Latest current report8-K2026-10-21
Latest proxyDEFA14A2026-04-01

Source: SEC EDGAR submissions feed, 932 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.1%
1 month+7.2%
3 months+12.4%
Year to date+16.4%
1 year+10.6%
From 52-week high-5.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Commercial Physical & Biological Resarch

TickerCompanyPriceDayMarket cap
CRLCharles River Laboratories International Inc.$335.52-0.72%$16.1B
ICLRICON plc$191.40-1.67%$14.7B
INCYIncyte Corp.$120.27-0.58%$24.5B
IQVIQVIA Holdings Inc.$264.73-0.15%$43.6B
ABSIAbsci Corporation$7.47-11.54%$1.3B
OABIOmniAb Inc.$4.89-0.41%$713.3M
NRCNRC Health$26.33-0.87%$558.8M
MXCTMaxCyte Inc.$1.18-0.84%$121.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier